ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMN ProMIS Neurosciences Inc

Post-Mkt 08-06 16:24:43 EDT

13.33

-0.15

-1.11%

盘后13.33

+0.000.00%

16:10 EDT

High13.79	Low13.27	Vol14.69K
Open13.34	D1 Closing13.48	Amplitude3.86%
Mkt Cap119.54M	Tradable Cap61.28M	Total Shares8.97M
T/O197.40K	T/O Rate0.32%	Tradable Shares4.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMN","market":"US","secType":"STK","nameCN":"ProMIS Neurosciences Inc","latestPrice":13.33,"timestamp":1786046400000,"preClose":13.48,"halted":0,"volume":14688,"hourTrading":{"tag":"盘后","latestPrice":13.33,"preClose":13.33,"latestTime":"16:10 EDT","volume":5,"amount":66.65,"timestamp":1786047005167,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011127596439169166,"floatShares":4597500,"shares":8967700,"eps":-18.6,"marketStatus":"Post-Mkt","change":-0.15,"latestTime":"08-06 16:24:43 EDT","open":13.34,"high":13.79,"low":13.27,"amount":197402,"amplitude":0.038576,"askPrice":14.1,"askSize":1,"bidPrice":13.27,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-18.6,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1786060800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":13.48,"preHourTrading":{"tag":"盘前","latestPrice":13.37,"preClose":13.48,"latestTime":"04:23 EDT","volume":1,"amount":13.37,"timestamp":1786004605597,"change":-0.11,"changeRate":-0.00816,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":13.33,"preClose":13.33,"latestTime":"16:10 EDT","volume":5,"amount":66.65,"timestamp":1786047005167,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.451372},"requestUrl":"/m/hq/s/PMN/","defaultTab":"news","newsList":[{"id":"2656092103","title":"ProMIS Neurosciences to Report Q2 Results, Host Investor Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2656092103","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656092103?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:00","pubTimestamp":1785787215,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences to report Q2 results, host investor call and webcastProMIS Neurosciences will report Q2 results ended June 30, 2026 on Aug. 13, 2026.Investor conference call, webcast set for Aug.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3YtX5s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","BCDF","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","PMN","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4585","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","SG9999014039.USD","BK4139","NDAQ","LU0314104364.USD","BK4112","SG9999014013.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530784","title":"ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530784","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530784?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:00","pubTimestamp":1785787200,"startTime":"0","endTime":"0","summary":"Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug.  03, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337849/0/en/ProMIS-Neurosciences-to-Report-Second-Quarter-2026-Financial-Results-and-Business-Update-on-August-13-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654885286","title":"ProMIS Neurosciences is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885286","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654885286?lang=en_us&edition=fundamental","pubTime":"2026-07-28 23:33","pubTimestamp":1785252780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654883429","title":"Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2654883429","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654883429?lang=en_us&edition=fundamental","pubTime":"2026-07-28 22:46","pubTimestamp":1785250014,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (PMN) has an average rating of buy and mean price target of $37.64, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654988849","title":"ProMIS Neurosciences Inc : Chardan Capital Markets Raises Target Price to $33 from $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2654988849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654988849?lang=en_us&edition=fundamental","pubTime":"2026-07-28 22:22","pubTimestamp":1785248575,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U19J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001746","title":"Analysts Offer Insights on Healthcare Companies: Opko Health (OPK), ProMIS Neurosciences (PMN) and The Ensign Group (ENSG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001746?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:50","pubTimestamp":1785239411,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Opko Health (OPK), ProMIS Neurosciences (PMN) and The Ensign Grou...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opko-health-opk-promis-neurosciences-pmn-and-the-ensign-group-ensg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opko-health-opk-promis-neurosciences-pmn-and-the-ensign-group-ensg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","HCSG","BK4185","BK4585","LABU","BK4588","LU0029874061.USD","LU0240877869.USD","LU0240878834.USD","BK4196","BK4137","BK4581","ENSG","XBI","PMN","OPK","LU0128526141.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654008053","title":"ProMIS Reports Positive Six-month Interim Safety, Biomarker Data for Pmn310 in Phase 1b Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654008053","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654008053?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:03","pubTimestamp":1785233023,"startTime":"0","endTime":"0","summary":"ProMIS reports positive six-month interim safety, biomarker data for PMN310 in Phase 1b Alzheimer’s trialProMIS Neurosciences released blinded six-month interim safety and biomarker data from its PREC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL7jJ9p4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654248008","title":"ProMIS Neurosciences - no Aria-E Observed Across All Genotypes Including Apoe4 Homozygotes in Interim Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2654248008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654248008?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:01","pubTimestamp":1785232896,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1OC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654008799","title":"ProMIS Neurosciences - Early Biomarker Movement Consistent with Target Engagement Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2654008799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654008799?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:01","pubTimestamp":1785232896,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1OC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654008711","title":"ProMIS Neurosciences - 12-Month Topline Results Expected in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2654008711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654008711?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:01","pubTimestamp":1785232896,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43T1OC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654025201","title":"ProMIS Neurosciences Shares Rise on Upcoming Alzheimer's Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2654025201","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654025201?lang=en_us&edition=fundamental","pubTime":"2026-07-28 05:54","pubTimestamp":1785189240,"startTime":"0","endTime":"0","summary":"Shares of ProMIS Neurosciences rose after the company said it will host a webinar to discuss six-month, blinded interim results from an early-stage study of its Alzheimer's antibody, PMN310.Shares were recently up about 17% at $13.69 in after-hThe  clinical-stage biotechnology company said the webinar is scheduled for 8 a.m. ET on Tuesday and will cover safety findings and overall trends in selected lab markers from patients in the study.ours trading Monday. The stock is up about 72% year to date.The update comes from a Phase 1b trial, an early study that tests safety and dosing in a small group of people and is still blinded, meaning individual results are not revealed yet.Write to Doc Louallen at Doc.Louallen@wsj.com Dow Jones NewswiresJuly 27, 2026 17:54 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654116900","title":"ProMIS Neurosciences Initiated at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2654116900","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654116900?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:37","pubTimestamp":1785148620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings(END) Dow Jones NewswiresJuly 27, 2026 06:37 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013331","title":"ProMIS Neurosciences initiated with a Buy at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654013331?lang=en_us&edition=fundamental","pubTime":"2026-07-27 16:20","pubTimestamp":1785140412,"startTime":"0","endTime":"0","summary":"Chardan analyst Keay Nakae initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $20 price target The firm cites the potential of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-initiated-with-a-buy-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-initiated-with-a-buy-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654090153","title":"Analysts Offer Insights on Healthcare Companies: Raffles Medical Group (OtherRAFLF), ProMIS Neurosciences (PMN) and Chugai Pharmaceutical Co (OtherCHGCF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654090153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654090153?lang=en_us&edition=fundamental","pubTime":"2026-07-27 15:30","pubTimestamp":1785137407,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Raffles Medical Group (RAFLF), ProMIS Neuroscience...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-raffles-medical-group-otherraflf-promis-neurosciences-pmn-and-chugai-pharmaceutical-co-otherchgcf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-raffles-medical-group-otherraflf-promis-neurosciences-pmn-and-chugai-pharmaceutical-co-otherchgcf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4137","BK4588","LU0029874061.USD","LU0128526141.USD","XBI","XLV","HCSG","RAFLF","PMN","BK4139","LABU","BK4585","BK4185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654761095","title":"Promis Neurosciences Inc : Chardan Capital Markets Initiates Coverage with Buy Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2654761095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654761095?lang=en_us&edition=fundamental","pubTime":"2026-07-27 10:42","pubTimestamp":1785120154,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nFWN43T000:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651709721","title":"Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651709721","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651709721?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:15","pubTimestamp":1784027733,"startTime":"0","endTime":"0","summary":"In a report released today, from Guggenheim maintained a Buy rating on ProMIS Neurosciences, with a price target of $35.00. In a report released on...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-promis-neurosciences-pmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-promis-neurosciences-pmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651792051","title":"ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310","url":"https://stock-news.laohu8.com/highlight/detail?id=2651792051","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651792051?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:35","pubTimestamp":1784021745,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (PMN) announced the first human evidence of dose-dependent amyloid-beta oligomer reduction by its Alzheimer’s drug candidate, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-reports-amyloid-beta-oligomer-reduction-by-pmn310-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-reports-amyloid-beta-oligomer-reduction-by-pmn310-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651214122","title":"Promis Neurosciences Says Pmn310 Cuts Amyloid-beta Oligomers in Human CSF in Phase 1a Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651214122","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651214122?lang=en_us&edition=fundamental","pubTime":"2026-07-14 14:30","pubTimestamp":1784010633,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences says PMN310 cuts amyloid-beta oligomers in human CSF in Phase 1a dataProMIS Neurosciences reported first human evidence that PMN310 reduced amyloid-beta oligomers in CSF in a Phas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDLccRdYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4139","BK4588","SG9999014039.USD","LU2095319765.USD","BK4112","SG9999014021.USD","PMN","LU0314104364.USD","IE00BKPKM429.USD","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","BCDF","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651203281","title":"ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651203281","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651203281?lang=en_us&edition=fundamental","pubTime":"2026-07-14 14:30","pubTimestamp":1784010600,"startTime":"0","endTime":"0","summary":"PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326583/0/en/ProMIS-Neurosciences-Reports-First-Human-Evidence-of-Amyloid-Beta-Oligomer-Target-Engagement-by-PMN310-at-AAIC-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649964967","title":"Promis Neurosciences Initiated at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964967","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649964967?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:19","pubTimestamp":1783502340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 05:19 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.promisneurosciences.com","stockEarnings":[{"period":"1week","weight":-0.0413},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.3713},{"period":"6month","weight":0.0589},{"period":"1year","weight":-0.1952},{"period":"ytd","weight":0.9751}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.492325},{"month":2,"riseRate":0.5,"avgChangeRate":0.1186},{"month":3,"riseRate":0,"avgChangeRate":-0.161081},{"month":4,"riseRate":0.5,"avgChangeRate":0.06597},{"month":5,"riseRate":0,"avgChangeRate":-0.137867},{"month":6,"riseRate":0.25,"avgChangeRate":-0.061162},{"month":7,"riseRate":0.5,"avgChangeRate":0.083188},{"month":8,"riseRate":0,"avgChangeRate":-0.151954},{"month":9,"riseRate":0.5,"avgChangeRate":-0.048217},{"month":10,"riseRate":0.25,"avgChangeRate":-0.042317},{"month":11,"riseRate":0,"avgChangeRate":-0.242658},{"month":12,"riseRate":0.5,"avgChangeRate":-0.058437}],"exchange":"NASDAQ","name":"ProMIS Neurosciences Inc","nameEN":"ProMIS Neurosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProMIS Neurosciences Inc,PMN,ProMIS Neurosciences Inc股票,ProMIS Neurosciences Inc股票老虎,ProMIS Neurosciences Inc股票老虎国际,ProMIS Neurosciences Inc行情,ProMIS Neurosciences Inc股票行情,ProMIS Neurosciences Inc股价,ProMIS Neurosciences Inc股市,ProMIS Neurosciences Inc股票价格,ProMIS Neurosciences Inc股票交易,ProMIS Neurosciences Inc股票购买,ProMIS Neurosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction